Ascletis Pharma Inc.

ASCLFOTCHealthcare● Active

$1.35

+$0.03(+2.27%)

Market Cap$1.4B

P/E Ratio—

52W High$2.5

52W Low$0.9325

Avg Volume679

Open$1.35

Beta0.40

Free Cash Flow Financials Revenue

Ascletis Pharma Inc. (ASCLF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ASCLF · free cash flow · updated Jun 9, 2026

Core FCF metrics

ASCLF · FCF · TTM · margin & CAGR

Free cash flow was −$330.9M for FY2025 (fiscal year ending 2025-12-31), up 3.7% year-over-year

FY2025 Free Cash Flow−$330.9M▲ +3.7% YoY

Trailing 12M (TTM)−$723.4Mtrailing 4 quarters sum

FCF Margin< −999%−$330.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ASCLF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$329.3M(2M)−$330.9M▲ +3.7%—

FY2024−$341.6M(2M)−$343.7M▼ 110.5%—

FY2023−$144.2M(19M)−$163.3M▼ 4.1%-288.6%

FY2022−$142.5M(14M)−$156.9M▼ 1.8%-290.0%

FY2021−$146.9M(7M)−$154.1M▼ 24.4%-200.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ASCLF · P/FCF · FCF yield · FCF per share

Ascletis Pharma Inc. (ASCLF) reported negative free cash flow of −$0.33B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ASCLF · cash flow statement · operating / investing / financing

For FY2025, Ascletis Pharma Inc. generated −$329.3M in operating cash flow and spent 2M in capital expenditures, yielding −$330.9M in free cash flow.

Operating Activities

−$329.3M

Cash from core business operations

2025-12-31

Investing Activities

+$566.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$336.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$329.3M) − |CapEx| (2M) = FCF (−$330.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ASCLF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Ascletis Pharma Inc.YOU

ASCLF

−$330.9M+3.7%-16746.4%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Ascletis Pharma Inc. (ASCLF) reported free cash flow of −$330.9M for FY2025 (fiscal year ending 2025-12-31), up 3.7% year-over-year.

Ascletis Pharma Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 10 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ASCLF free cash flow · 8 questions

Ascletis Pharma Inc. free cash flow was −$330.9M for FY2025, up 3.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$723.4M.

ASCLF free cash flowASCLF FCFASCLF FCF 2025ASCLF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Ascletis Pharma Inc. · Ascletis Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026